Medicilon topped the "Top 10 Most Influential CRO Enterprises" in the 2023 China Biopharmaceutical Industry Value List

On June 29, the 9th China Bio-Pharma Innovation Cooperation Conference (BIO-PHARM2023) and the 2023 China Biopharmaceutical Industry Value List Awards Ceremony were grandly opened in Suzhou.  Shanghai Medicilon Inc. was listed in the "Top 10 Most Influential CRO Enterprises" of the 2023 China Biopharmaceutical Industry Value List by virtue of its excellent R&D capabilities and outstanding innovative service platform.

The Huayi List - 2023 China Biopharmaceutical Industry Value List is established by the Huayi Research Institute through selection, aiming to discover innovative companies with real industry influence and growth potential in the field of biopharmaceutical.  Huayi Research Institute is one of the few medical investment research institutes in China, and is also the definer of the China medical investment.  The value list consists of five series of selections: antibody drugs, innovative therapies, biotechnology, CRO, and CDMO, and the selection was based on the enterprise quantitative growth evaluation standard by the Huayi Research Institute and combined with basic processes such as questionnaire survey, enterprise interview, data analysis and verification.  After the review team conducts standardized processing and quantitative evaluation of the data of biomedical shortlisted companies, the companies with significant industry value of the year will be selected.